V-006
Valproic acid solution
1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
로그인조직 및 계약 가격 보기
크기 선택
제품정보 (DICE 배송 시 비용 별도)
실험식(Hill 표기법):
C8H16O2
CAS 번호:
Molecular Weight:
144.21
EC Number:
MDL number:
UNSPSC 코드:
41116107
NACRES:
NA.24
Grade
certified reference material
Quality Level
양식
liquid
특징
Snap-N-Spike®/Snap-N-Shoot®
포장
ampule of 1 mL
제조업체/상표
Cerilliant®
농도
1.0 mg/mL in methanol
기술
gas chromatography (GC): suitable
liquid chromatography (LC): suitable
응용 분야
clinical testing
형식
single component solution
저장 온도
−20°C
SMILES string
CCCC(CCC)C(O)=O
InChI
1S/C8H16O2/c1-3-5-7(6-4-2)8(9)10/h7H,3-6H2,1-2H3,(H,9,10)
InChI key
NIJJYAXOARWZEE-UHFFFAOYSA-N
유전자 정보
human ... ALDH5A1(7915)
일반 설명
A Certified Spiking Solution® suitable for use in LC/MS or GC/MS applications in clinical toxicology, forensic analysis, urine drug testing, prescription monitoring or pharmaceutical research. Valproic acid, sold under trade names including Depakote®, Valparin, or Stavzor®, is an antiepileptic drug and mood stabilizer. The drug is prescribed for treatment of epilepsy, bipolar disorder, migraine headaches, and depression.
법적 정보
CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
CERTIFIED SPIKING SOLUTION is a registered trademark of Cerilliant Corporation
Depakote is a registered trademark of Sanofi S.A.
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
Stavzor is a registered trademark of Noven Therapeutics, LLC
신호어
Danger
유해 및 위험 성명서
Hazard Classifications
Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1
표적 기관
Eyes,Central nervous system
Storage Class Code
3 - Flammable liquids
WGK
WGK 2
Flash Point (°F)
49.5 °F - closed cup
Flash Point (°C)
9.7 °C - closed cup
시험 성적서(COA)
제품의 로트/배치 번호를 입력하여 시험 성적서(COA)을 검색하십시오. 로트 및 배치 번호는 제품 라벨에 있는 ‘로트’ 또는 ‘배치’라는 용어 뒤에서 찾을 수 있습니다.
Emily C Bell et al.
Human psychopharmacology, 20(6), 415-424 (2005-08-18)
Previous functional imaging studies have shown altered brain activity during cognitive task performance in bipolar patients. However, the fact that these patients are often on medication makes it unclear to what extent these changes reflect treatment effects. This study aims
Wolfgang Löscher
CNS drugs, 16(10), 669-694 (2002-09-25)
Since its first marketing as an antiepileptic drug (AED) 35 years ago in France, valproate has become established worldwide as one of the most widely used AEDs in the treatment of both generalised and partial seizures in adults and children.
Heath R Pardoe et al.
Neurology, 80(20), 1895-1900 (2013-04-26)
We hypothesized that total brain volume, white matter volume, and lobar cortical thickness would be different in epilepsy patients. We studied valproate relative to nonvalproate by using patients with epilepsy and healthy controls. Patients with focal intractable epilepsy from a
S Eyal et al.
British journal of pharmacology, 149(3), 250-260 (2006-08-09)
The antiepileptic drug valproic acid, a histone deacetylase (HDAC) inhibitor, is currently being tested as an anticancer agent. However, HDAC inhibitors may interact with anticancer drugs through induction of P-glycoprotein (P-gp, MDR1) expression. In this study we assessed whether valproic
Matthew D Sztajnkrycer
Journal of toxicology. Clinical toxicology, 40(6), 789-801 (2002-12-12)
Acute valproic acid intoxication is an increasing problem, accounting for more than 5000 calls to the American Association of Poison Control Centers in 2000. The purpose of this paper is to review the pharmacology and toxicology of valproic acid toxicity.
자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..
고객지원팀으로 연락바랍니다.